Cargando…

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling

Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiya, Naoyuki, Murai, Moeka, Hosoda, Ayumi, Yonezawa, Honami, Omori, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/
https://www.ncbi.nlm.nih.gov/pubmed/31703435
http://dx.doi.org/10.3390/ph12040165
_version_ 1783487401726836736
author Nishiya, Naoyuki
Murai, Moeka
Hosoda, Ayumi
Yonezawa, Honami
Omori, Norikazu
author_facet Nishiya, Naoyuki
Murai, Moeka
Hosoda, Ayumi
Yonezawa, Honami
Omori, Norikazu
author_sort Nishiya, Naoyuki
collection PubMed
description Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival of the therapies. Therefore, controlling adverse effects not only facilitates treatment continuation but also increases clinical benefits. In this study, we proposed a novel strategy for reducing EGFR–tyrosine kinase inhibitor (TKI)-induced adverse effects in nontumorous organs by repositioning approved medicines using a zebrafish model. We developed a model system for evaluating chemical quenchers of afatinib, a clinically available irreversible EGFR-TKI, by scoring the inhibition of afatinib-induced hyperformation of lateral line neuromasts in zebrafish larvae. Bucillamine, an antirheumatic drug, was identified as an afatinib quencher in the zebrafish system and inhibited TKI activity in vitro. In addition, bucillamine restored EGFR autophosphorylation and downstream signaling in afatinib-treated A431 cells. Thus, topical bucillamine is a potential reliever of irreversible EGFR-TKI-induced skin rash. The zebrafish model can be applied to a screening for quenchers of other anti-EGFR-targeting therapies, including reversible TKIs and biologics.
format Online
Article
Text
id pubmed-6958386
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69583862020-01-23 Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling Nishiya, Naoyuki Murai, Moeka Hosoda, Ayumi Yonezawa, Honami Omori, Norikazu Pharmaceuticals (Basel) Article Molecular targeting therapies often cause characteristic adverse effects, such as skin rash during anti-epidermal growth factor receptor (EGFR) therapies, making treatment continuation difficult. In contrast, skin symptoms induced by EGFR inhibition are strongly correlated with the overall survival of the therapies. Therefore, controlling adverse effects not only facilitates treatment continuation but also increases clinical benefits. In this study, we proposed a novel strategy for reducing EGFR–tyrosine kinase inhibitor (TKI)-induced adverse effects in nontumorous organs by repositioning approved medicines using a zebrafish model. We developed a model system for evaluating chemical quenchers of afatinib, a clinically available irreversible EGFR-TKI, by scoring the inhibition of afatinib-induced hyperformation of lateral line neuromasts in zebrafish larvae. Bucillamine, an antirheumatic drug, was identified as an afatinib quencher in the zebrafish system and inhibited TKI activity in vitro. In addition, bucillamine restored EGFR autophosphorylation and downstream signaling in afatinib-treated A431 cells. Thus, topical bucillamine is a potential reliever of irreversible EGFR-TKI-induced skin rash. The zebrafish model can be applied to a screening for quenchers of other anti-EGFR-targeting therapies, including reversible TKIs and biologics. MDPI 2019-11-07 /pmc/articles/PMC6958386/ /pubmed/31703435 http://dx.doi.org/10.3390/ph12040165 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nishiya, Naoyuki
Murai, Moeka
Hosoda, Ayumi
Yonezawa, Honami
Omori, Norikazu
Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title_full Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title_fullStr Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title_full_unstemmed Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title_short Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
title_sort bucillamine prevents afatinib-mediated inhibition of epidermal growth factor receptor signaling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958386/
https://www.ncbi.nlm.nih.gov/pubmed/31703435
http://dx.doi.org/10.3390/ph12040165
work_keys_str_mv AT nishiyanaoyuki bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling
AT muraimoeka bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling
AT hosodaayumi bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling
AT yonezawahonami bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling
AT omorinorikazu bucillaminepreventsafatinibmediatedinhibitionofepidermalgrowthfactorreceptorsignaling